SNDX Q3 2020 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379,000+0.0% YoY

Gross Profit

$379,000100.0% margin

Operating Income

-$20M-5238.3% margin

Net Income

-$20M-5392.3% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$179M

Total Liabilities

$47M

Stockholders' Equity

$132M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379,000	$379,000	+0.0%
Gross Profit	$379,000	$379,000	+0.0%
Operating Income	-$20M	-$13M	-51.0%
Net Income	-$20M	-$13M	-59.3%